[Effect of danazol treatment on growth in pediatric patients with hereditary angioedema due to C1-inhibitor deficiency].

INTRODUCTION Attenuated androgens are used for the prevention of angioedema attacks of hereditary angioedema with C1-inhibitor deficiency. After prepuberty, their use can lead to growth retardation. AIM We assessed the effect of danazol on the growth of pediatric patients with hereditary angioedema. METHOD In the retrospective study on 42 patients diagnosed with hereditary angioedema, we calculated the deviation from the mid-parental target height, and analyzed it against the gender, the dose and duration of danazol treatment administered before the age of 21 years and before the age of 16 years. RESULTS Regarding the deviation from the mid-parental target height, we did not find any significant difference between patients taking vs. not taking danazol, males vs. females taking danazol. The dose and the duration of danazol treatment did not influence that value neither before 21, nor before 16 years of age. CONCLUSIONS Our findings suggest that treatment with the lowest effective doses of danazol does not influence growth. Orv Hetil. 2017; 158(32): 1269-1276.

[1]  H. Farkas,et al.  The effect of long-term danazol treatment on haematological parameters in hereditary angioedema , 2016, Orphanet Journal of Rare Diseases.

[2]  D. Panagiotakos,et al.  Establishing cross-sectional curves for height, weight, body mass index and waist circumference for 4- to 18-year-old Greek children, using the Lambda Mu and Sigma (LMS) statistical method. , 2015, Hippokratia.

[3]  S. Burdach,et al.  Immune Thrombocytopenia in Two Unrelated Fanconi Anemia Patients – A Mere Coincidence? , 2015, Front. Pediatr..

[4]  H. Farkas,et al.  Frequency of the virilising effects of attenuated androgens reported by women with hereditary angioedema , 2014, Orphanet Journal of Rare Diseases.

[5]  D. Smeets,et al.  Karyotype-Specific Ear and Hearing Problems in Young Adults With Turner Syndrome and the Effect of Oxandrolone Treatment , 2014, Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology.

[6]  M. Triggiani,et al.  Classification, diagnosis, and approach to treatment for angioedema: consensus report from the Hereditary Angioedema International Working Group , 2014, Allergy.

[7]  H. Farkas,et al.  The influence of trigger factors on hereditary angioedema due to C1-inhibitor deficiency , 2014, Orphanet Journal of Rare Diseases.

[8]  H. Farkas.  Current pharmacotherapy of bradykinin-mediated angioedema , 2013, Expert opinion on pharmacotherapy.

[9]  R. Lockey,et al.  WAO Guideline for the Management of Hereditary Angioedema , 2012, The World Allergy Organization journal.

[10]  M. Davenport.  Growth hormone therapy in Turner syndrome. , 2012, Pediatric endocrinology reviews : PER.

[11]  M. Triggiani,et al.  Evidence‐based recommendations for the therapeutic management of angioedema owing to hereditary C1 inhibitor deficiency: consensus report of an International Working Group , 2012, Allergy.

[12]  T. Bowen.  Hereditary angioedema: beyond international consensus - circa December 2010 - The Canadian Society of Allergy and Clinical Immunology Dr. David McCourtie Lecture , 2011, Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology.

[13]  A. Kaplan,et al.  The plasma bradykinin-forming pathways and its interrelationships with complement. , 2010, Molecular immunology.

[14]  J. Aharon-Peretz,et al.  Androgen replacement therapy in Turner syndrome: a pilot study. , 2009, The Journal of clinical endocrinology and metabolism.

[15]  K. Bork,et al.  Benefits and risks of danazol in hereditary angioedema: a long-term survey of 118 patients. , 2008, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[16]  L. Petersen,et al.  Genetic and environmental influences on the relation between parental social class and mortality. , 2006, International journal of epidemiology.

[17]  M. Osler,et al.  Validity of protein, retinol, folic acid and n–3 fatty acid intakes estimated from the food-frequency questionnaire used in the Danish National Birth Cohort , 2006, Public Health Nutrition.

[18]  P. Ruzza,et al.  Fluorescent, internally quenched, peptides for exploring the pH‐dependent substrate specificity of cathepsin B , 2006, Journal of peptide science : an official publication of the European Peptide Society.

[19]  M. Osler,et al.  Influence of marital history over two and three generations on early death. A longitudinal study of Danish men born in 1953 , 2006, Journal of Epidemiology and Community Health.

[20]  T. Osler,et al.  Incorporating recent advances to make the TRISS approach universally available. , 2006, The Journal of trauma.

[21]  L. Romics,et al.  Adverse effects of danazol prophylaxis on the lipid profiles of patients with hereditary angioedema. , 2005, The Journal of allergy and clinical immunology.

[22]  H. Farkas,et al.  The Hungarian HAE experience. , 2003, Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis.

[23]  M. Cicardi,et al.  Increased expression of C1-inhibitor mRNA in patients with hereditary angioedema treated with Danazol. , 2003, Immunology letters.

[24]  N. Shahidi.  A review of the chemistry, biological action, and clinical applications of anabolic-androgenic steroids. , 2001, Clinical therapeutics.

[25]  P. Mannucci,et al.  Activation of the coagulation cascade in C1-inhibitor deficiencies. , 1997, Blood.

[26]  L. Uzych,et al.  Anabolic-Androgenic Steroids and Psychiatric-Related Effects: A Review* , 1992, Canadian journal of psychiatry. Revue canadienne de psychiatrie.

[27]  J. Cohen,et al.  Insulin resistance and diminished glucose tolerance in powerlifters ingesting anabolic steroids. , 1987, The Journal of clinical endocrinology and metabolism.

[28]  M. Alen,et al.  Testicular responsiveness to human chorionic gonadotrophin during transient hypogonadotrophic hypogonadism induced by androgenic/anabolic steroids in power athletes. , 1986, Journal of steroid biochemistry.

[29]  A. Kitabchi,et al.  Glucose intolerance and insulin resistance in aplastic anemia treated with oxymetholone. , 1981, The Journal of clinical endocrinology and metabolism.

[30]  E. Brown,et al.  Long-term therapy of hereditary angioedema with danazol. , 1980, Annals of internal medicine.

[31]  A. Sheffer,et al.  Clinical and biochemical effects of impeded androgen (oxymetholone) therapy of hereditary angioedema. , 1979, The Journal of allergy and clinical immunology.

[32]  C. Migeon,et al.  The effect of danazol in sexual precocity. , 1975, The Johns Hopkins medical journal.

[33]  M. Osler.  [Estrogens and liver diseases]. , 1974, Ugeskrift for læger.

[34]  J. Worley,et al.  Study of an anabolic steroid. Certain effects of oxymetholone on small children. , 1967, American journal of diseases of children.

[35]  J. Naets,et al.  THE MECHANISM OF ACTION OF ANDROGENS ON ERYTHROPOIESIS * , 1965, Annals of the New York Academy of Sciences.

[36]  N. Talbot,et al.  The use of methyltestosterone to stimulate growth: relative influence on skeletal maturation and linear growth. , 1956, The Journal of clinical endocrinology and metabolism.

[37]  C. S. Smith,et al.  The role of danazol in the management of precocious puberty. , 1979, Postgraduate medical journal.

[38]  D. Alling,et al.  Treatment of hereditary angioedema with danazol. Reversal of clinical and biochemical abnormalities. , 1976, The New England journal of medicine.